vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-665Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWМеждународный опыт применения абатацепта для лечения рефрактерного увеита у пациентов с ювенильным идиопатическим артритомINTERNATIONAL PRACTICE OF ABATACEPT USE IN TREATMENT OF REFRACTORY UVEITIS IN PATIENTS WITH IDIOPATHIC JUVENILE ARTHRITISДенисоваР.В.DenisovaR.V.neonatepearl@yandex.ruАлексееваЕ.И.AlexeevaE.I.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, МоскваScientific Center of Children’s Health RAMS, MoscowНаучный центр здоровья детей РАМН, Москва
Первый Московский государственный медицинский университет им. И.М. СеченоваScientific Center of Children’s Health RAMS, Moscow
Sechenov First Moscow State Medical University201116092011105Вопросы современной педиатрии3944Copyright © Денисова Р., Алексеева Е., 20112011Денисова Р., Алексеева Е.Denisova R., Alexeeva E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/665ReferencesSaurenmann R.K., Levin A.V., Feldman B.M. et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long term follow up study. Arthritis. Rheum. 2007; 56: 647–657.Saurenmann R.K., Levin A.V., Feldman B.M. et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long term follow up study. Arthritis. Rheum. 2007; 56: 647–657.Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti–inflammatory medication. Eur. J. Ophthalmol. 2007; 17: 743–748.Heiligenhaus A., Mingels A., Heinz C., Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti–inflammatory medication. Eur. J. Ophthalmol. 2007; 17: 743–748.Tappeiner C., Roesel M., Heinz C. et al. Limited value of cyclosporine for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye. 2009; 23: 1192–1198.Tappeiner C., Roesel M., Heinz C. et al. Limited value of cyclosporine for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye. 2009; 23: 1192–1198.Doycheva D., Deuter C., Stuebiger N. et al. Mycophenolate mofetil in the treatment of uveitis in children. Br. J. Ophthalmol. 2007; 91: 180–184.Doycheva D., Deuter C., Stuebiger N. et al. Mycophenolate mofetil in the treatment of uveitis in children. Br. J. Ophthalmol. 2007; 91: 180–184.Sharma S.M., Ramanan A.V., Riley P., Dick A.D. Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: efficacy in joint and ocular disease [letter]. Ann. Rheum. Dis. 2007; 66: 840–841.Sharma S.M., Ramanan A.V., Riley P., Dick A.D. Use of infliximab in juvenile onset rheumatological disease associated refractory uveitis: efficacy in joint and ocular disease [letter]. Ann. Rheum. Dis. 2007; 66: 840–841.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91: 319–324.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007; 91: 319–324.Pettit A.R., Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis. Immunol. Cell. Biol. 1999; 7: 420–427.Pettit A.R., Thomas R. Dendritic cells: the driving force behind autoimmunity in rheumatoid arthritis. Immunol. Cell. Biol. 1999; 7: 420–427.Bretscher P.A. A two step, two signal model for the primary activation of precursor helper T– cells. Proc. Natl. Acad. Sci. USA. 1999; 96: 85–90.Bretscher P.A. A two step, two signal model for the primary activation of precursor helper T– cells. Proc. Natl. Acad. Sci. USA. 1999; 96: 85–90.Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 2001; 344: 907–916.Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl. J. Med. 2001; 344: 907–916.Yamada A., Salama A.D., Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 2002; 13: 559–575.Yamada A., Salama A.D., Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 2002; 13: 559–575.Chambers C.A., Allison J.P. CTLA–4 — the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold. Spring. Harb. Symp. Quant. Biol. 1999; 64: 303–312.Chambers C.A., Allison J.P. CTLA–4 — the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold. Spring. Harb. Symp. Quant. Biol. 1999; 64: 303–312.Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement dependent сytotoxicity or antibody dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement dependent сytotoxicity or antibody dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.Linsley P.S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.Linsley P.S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.Алексеева Е.И., Денисова Р.В., Валиева С.И. Абатацепт — новые возможности терапии ювенильного идиопатического артрита. Вопросы современной педиатрии. 2009; 8 (4): 84–89.Алексеева Е.И., Денисова Р.В., Валиева С.И. Абатацепт — новые возможности терапии ювенильного идиопатического артрита. Вопросы современной педиатрии. 2009; 8 (4): 84–89.Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis — a case report. J. Rheumatol. 2008; 35 (9): 1897–1898.Angeles-Han S., Flynn T., Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis — a case report. J. Rheumatol. 2008; 35 (9): 1897–1898.Zulian F., Balzarin M., Falcini F. Abatacept for Severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis — related uveitis. Arthritis. Care. Research. 2010; 62 (6): 821–825.Zulian F., Balzarin M., Falcini F. Abatacept for Severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis — related uveitis. Arthritis. Care. Research. 2010; 62 (6): 821–825.Kenawy N., Cleary G., Mewar D. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis associated uveitis. Graefes. Arch. Clin. Exp. Ophthalmol. 2011; 249 (2): 297–300.Kenawy N., Cleary G., Mewar D. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis associated uveitis. Graefes. Arch. Clin. Exp. Ophthalmol. 2011; 249 (2): 297–300.Elhai M., Deslandre C.J., Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases.Arthritis. Care. Res. (Hoboken). 2011; 63 (2): 307–308.Elhai M., Deslandre C.J., Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases.Arthritis. Care. Res. (Hoboken). 2011; 63 (2): 307–308.Silver P.B., Hathcock K.S., Chan C.C. et al. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long term tolerance. J. Immunol. 2000; 165: 5041–5047.Silver P.B., Hathcock K.S., Chan C.C. et al. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long term tolerance. J. Immunol. 2000; 165: 5041–5047.Shao H., Woon M.D., Nakamura S. et al. Requirement of B7–mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2001; 42: 2016–2021.Shao H., Woon M.D., Nakamura S. et al. Requirement of B7–mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2001; 42: 2016–2021.Deschenes J., Char D.H., Kaleta S. Activated T lymphocytes in uveitis. Br. J. Ophthalmol. 1988; 72: 83–87.Deschenes J., Char D.H., Kaleta S. Activated T lymphocytes in uveitis. Br. J. Ophthalmol. 1988; 72: 83–87.Wang X.C., Norose K., Yano A. et al. Two color flow cytometric analysis of activated T lymphocytes in aqueous humor of patients with endogenous vs. exogenous uveitis. Curr. Eye. Res. 1995; 14: 425–433.Wang X.C., Norose K., Yano A. et al. Two color flow cytometric analysis of activated T lymphocytes in aqueous humor of patients with endogenous vs. exogenous uveitis. Curr. Eye. Res. 1995; 14: 425–433.
The authors declare that there are no conflicts of interest present.